238 related articles for article (PubMed ID: 30672165)
21. Evaluation of the accuracy of multiparametric MRI for predicting prostate cancer pathology and tumour staging in the real world: an multicentre study.
Kam J; Yuminaga Y; Krelle M; Gavin D; Koschel S; Aluwihare K; Sutherland T; Skinner S; Brennan J; Wong LM; Louie-Johnsun M
BJU Int; 2019 Aug; 124(2):297-301. PubMed ID: 30714285
[TBL] [Abstract][Full Text] [Related]
22. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
[No Abstract] [Full Text] [Related]
23. Tumor localization by Prostate Imaging and Reporting and Data System (PI-RADS) version 2.1 predicts prognosis of prostate cancer after radical prostatectomy.
Fujimoto A; Sakamoto S; Horikoshi T; Zhao X; Yamada Y; Rii J; Takeuchi N; Imamura Y; Sazuka T; Matsusaka K; Ikeda JI; Ichikawa T
Sci Rep; 2023 Jun; 13(1):10079. PubMed ID: 37344491
[TBL] [Abstract][Full Text] [Related]
24. [Implications of PI-RADS Version 1 and Updated Version 2 on the Scoring of Prostatic Lesions in Multiparametric MRI].
Haas M; Günzel K; Penzkofer T; Maxeiner A; Fischer T; Miller K; Hamm B; Asbach P; Cash H
Aktuelle Urol; 2016 Sep; 47(5):383-7. PubMed ID: 27680189
[TBL] [Abstract][Full Text] [Related]
25. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
26. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
[TBL] [Abstract][Full Text] [Related]
27. Implications of unconventional histological subtypes on magnetic resonance imaging and oncological outcomes in patients who have undergone radical prostatectomy.
Kurokawa K; Yamada Y; Sakamoto S; Horikoshi T; Sato K; Nanba S; Kubota Y; Kanesaka M; Fujimoto A; Takeuchi N; Shibata H; Sazuka T; Imamura Y; Tsuzuki T; Uno T; Ichikawa T
Sci Rep; 2024 Jun; 14(1):14868. PubMed ID: 38937563
[TBL] [Abstract][Full Text] [Related]
28. Application of Prostate Imaging Reporting and Data System Version 2 (PI-RADS v2): Interobserver Agreement and Positive Predictive Value for Localization of Intermediate- and High-Grade Prostate Cancers on Multiparametric Magnetic Resonance Imaging.
Chen F; Cen S; Palmer S
Acad Radiol; 2017 Sep; 24(9):1101-1106. PubMed ID: 28546032
[TBL] [Abstract][Full Text] [Related]
29. Prostate MRI evolution in clinical practice: Audit of tumour detection and staging versus prostatectomy with staged introduction of multiparametric MRI and Prostate Imaging Reporting and Data System v2 reporting.
Raeside M; Low A; Cohen P; Sutherland P; Gormly K
J Med Imaging Radiat Oncol; 2019 Aug; 63(4):487-494. PubMed ID: 30951248
[TBL] [Abstract][Full Text] [Related]
30. Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard.
Schaudinn A; Gawlitza J; Mucha S; Linder N; Franz T; Horn LC; Kahn T; Busse H
Eur J Radiol; 2019 Jul; 116():180-185. PubMed ID: 31153562
[TBL] [Abstract][Full Text] [Related]
31. Prostate Cancer: PI-RADS Version 2 Helps Preoperatively Predict Clinically Significant Cancers.
Park SY; Jung DC; Oh YT; Cho NH; Choi YD; Rha KH; Hong SJ; Han K
Radiology; 2016 Jul; 280(1):108-16. PubMed ID: 26836049
[TBL] [Abstract][Full Text] [Related]
32. Clinically insignificant prostate cancer suitable for active surveillance according to Prostate Cancer Research International: Active surveillance criteria: Utility of PI-RADS v2.
Yim JH; Kim CK; Kim JH
J Magn Reson Imaging; 2018 Apr; 47(4):1072-1079. PubMed ID: 28901655
[TBL] [Abstract][Full Text] [Related]
33. 1.5-T multiparametric MRI using PI-RADS: a region by region analysis to localize the index-tumor of prostate cancer in patients undergoing prostatectomy.
Reisæter LA; Fütterer JJ; Halvorsen OJ; Nygård Y; Biermann M; Andersen E; Gravdal K; Haukaas S; Monssen JA; Huisman HJ; Akslen LA; Beisland C; Rørvik J
Acta Radiol; 2015 Apr; 56(4):500-11. PubMed ID: 24819231
[TBL] [Abstract][Full Text] [Related]
34. Impact of Clinical History on Maximum PI-RADS Version 2 Score: A Six-Reader 120-Case Sham History Retrospective Evaluation.
Shankar PR; Kaza RK; Al-Hawary MM; Masch WR; Curci NE; Mendiratta-Lala M; Sakala MD; Johnson TD; Davenport MS
Radiology; 2018 Jul; 288(1):158-163. PubMed ID: 29664338
[TBL] [Abstract][Full Text] [Related]
35. Preoperative MRI PI-RADS scores are associated with prostate cancer upstaging on surgical pathology.
Pockros B; Stensland KD; Parries M; Frankenberger E; Canes D; Moinzadeh A
Prostate; 2022 Feb; 82(3):352-358. PubMed ID: 34878175
[TBL] [Abstract][Full Text] [Related]
36. Improving the detection rate of prostate cancer in the gray zone of PI-RADS v2 and serum tPSA by using prostate-specific antigen-age volume.
Lu YF; Zhang Q; Chen HY; Chen JY; Pan Y; Xu CC; Xu JX; Yu RS
Medicine (Baltimore); 2019 Jun; 98(26):e16289. PubMed ID: 31261602
[TBL] [Abstract][Full Text] [Related]
37. MR-based prognostic nomogram for prostate cancer after radical prostatectomy.
Zhang YD; Wu CJ; Bao ML; Li H; Wang XN; Liu XS; Shi HB
J Magn Reson Imaging; 2017 Feb; 45(2):586-596. PubMed ID: 27654116
[TBL] [Abstract][Full Text] [Related]
38. Baseline Multiparametric MRI for Selection of Prostate Cancer Patients Suitable for Active Surveillance: Which Features Matter?
Sanguedolce F; Petralia G; Sokhi H; Tagliabue E; Anyamene N; Hellawell G; Padhani AR
Clin Genitourin Cancer; 2018 Apr; 16(2):155-163.e6. PubMed ID: 29198639
[TBL] [Abstract][Full Text] [Related]
39. Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
Deniffel D; Salinas E; Ientilucci M; Evans AJ; Fleshner N; Ghai S; Hamilton R; Roberts A; Toi A; van der Kwast T; Zlotta A; Finelli A; Haider MA; Perlis N
J Urol; 2020 Dec; 204(6):1187-1194. PubMed ID: 32496160
[TBL] [Abstract][Full Text] [Related]
40. Intraductal carcinoma of the prostate (IDC-P) lowers apparent diffusion coefficient (ADC) values among intermediate risk prostate cancers.
Currin S; Flood TA; Krishna S; Ansari A; McInnes MDF; Schieda N
J Magn Reson Imaging; 2019 Jul; 50(1):279-287. PubMed ID: 30585372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
